Insider Trading Watch List: Kite Pharma Inc (KITE)

Kite Pharma Inc (NASDAQ:KITE) insider has recently participated in insider trading activity. Chief Scientific Officer, Roberts Margo R sold 18,750 shares for $1,202,964 via one transaction Feb 12. Following the transaction, the insider now owns 9,098 shares in total, priced at $408,409.22 as of Tuesday. Another notable insider trading was done by the same insider on Feb 02. BUTITTA CYNTHIA M sold1,900 shares at an average price of $50.13 for a total of $95,247. Moreover, Better Marc carried out a sale of 9,000 shares at $47.34 each on Feb 01. The transaction amounted to $426,036. COO and CFO BUTITTA CYNTHIA M sold8,100 shares for $418,128 through one transaction Jan 27. Following this sale, this insider’s stake in the company comprises 94,007 shares, priced at $4219974.2 as of Tuesday.

The stock has experienced a total of 23 insider trades in the past three months. These trades include 14 sell activities and 9 buy trades. Furthermore, over the past 12 months, the stock was traded 72 times by insiders. In 63 of these trades, the insider was a seller while an employee of the company was the buyer in just 9 instances.

Kite Pharma Inc (KITE) on February 16, 2016announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference.

Event: 2016 RBC Capital Markets Global Healthcare Conference

• Date: Tuesday, February 23, 2016


• Time:             4:05 PM Eastern Time


• Location: New York, NY

A live audio webcast will be available on the Investors section of Kite’s website, www.kitepharma.com.  A replay of the webcast will be available on the website for approximately 30 days.

Additionally, on Jan. 13, 2016 (KITE)announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection.

Under the terms of the agreement, Kite Pharma EU will partner with the LUMC Department of Clinical Oncology and Professor Dr. Sjoerd van der Burg, a leader in the research of HPV-associated cancers.   Kite will also receive an exclusive option to license multiple TCR gene sequences for the development and commercialization of product candidates.

“This collaboration expands our existing TCR franchise targeting HPV-associated cancers and creates an opportunity to broaden the coverage of human leukocyte antigen (HLA) types across different patient populations,” said David Chang, M.D., Ph.D., Chief Medical Officer and Executive Vice President of Research and Development of Kite. “LUMC is an ideal partner, given its deep experience with the immune response to solid tumors, and complements our existing research and development capabilities in Europe.”